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Abstract
Background.Major depressive disorder (MDD) is a common mood disorder, with a heritabil-
ity of around 34%. Molecular genetic studies made significant progress and identified genetic
markers associated with the risk of MDD; however, progress is slowed down by substantial
heterogeneity as MDD is assessed differently across international cohorts. Here, we used a
standardized online approach to measure MDD in multiple cohorts in the Netherlands and
evaluated whether this approach can be used in epidemiological and genetic association stud-
ies of depression.
Methods. Within the Biobank Netherlands Internet Collaboration (BIONIC) project, we col-
lected MDD data in eight cohorts involving 31 936 participants, using the online Lifetime
Depression Assessment Self-report (LIDAS), and estimated the prevalence of current and life-
time MDD in 22 623 unrelated individuals. In a large Netherlands Twin Register (NTR) twin-
family dataset (n≈ 18 000), we estimated the heritability of MDD, and the prediction of MDD
in a subset (n = 4782) through Polygenic Risk Score (PRS).
Results. Estimates of current and lifetime MDD prevalence were 6.7% and 18.1%, respectively,
in line with population estimates based on validated psychiatric interviews. In the NTR her-
itability estimates were 0.34/0.30 (S.E. = 0.02/0.02) for current/lifetime MDD, respectively,
showing that the LIDAS gives similar heritability rates for MDD as reported in the literature.
The PRS predicted risk of MDD (OR 1.23, 95% CI 1.15–1.32, R2 = 1.47%).
Conclusions. By assessing MDD status in the Netherlands using the LIDAS instrument, we
were able to confirm previously reported MDD prevalence and heritability estimates, which
suggests that this instrument can be used in epidemiological and genetic association studies
of depression.
Introduction
Major depressive disorder (MDD) is a common, complex mood disorder. Multiple factors of
biological as well as environmental origin are affecting the risk to develop MDD (Otte et al.,
2016). The 12-month and lifetime prevalence of MDD were estimated as 5.5% and 14.6% in
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high-income countries in the World Mental Health survey
(Bromet et al., 2011). In line with global estimates, the
12-month and lifetime MDD prevalence were 5.2% and 18.7%
in the Netherlands, respectively, based on Composite
International Diagnostic Interview 3.0 (CIDI) (de Graaf, Ten
Have, van Gool, & van Dorsselaer, 2012; Kessler & Üstün,
2004). The prevalence of MDD varies with socio-demographic
factors (Kessler & Bromet, 2013). Females are more likely to
develop MDD than males, the prevalence of both 12-month
and lifetime MDD tends to change with age and individuals
with a lower level of education are at higher risk of depression,
as compared to those with a higher level of education (Bijl,
Ravelli, & Van Zessen, 1998; Bromet et al., 2011; de Graaf et al.,
2012).
Both genetic as well as environmental factors play a role in the
liability to and the manifestation of MDD. Family studies find a
significantly higher prevalence of MDD in biological relatives of
MDD probands (Sullivan, Neale, & Kendler, 2000). Genetically
informative studies have shown that this familial component is
due to genetic factors rather than shared environmental risk.
The meta-analytic heritability estimate of a depressive episode
(according to ICF/ICD-10 classification) is 34% (Polderman
et al., 2015). Heritability of lifetime MDD, estimated across four
recall intervals in at least three interviews over a period of 9
years ranged between 34% and 41% with non-significant differ-
ences, indicating that the estimates do not depend on recall bias
(Kendler & Aggen, 2001). Twin studies also looked into sex-
specific heritability. Some studies reported no or little difference
between sexes (Kendler & Prescott, 1999; Nivard et al., 2015),
whereas some reported a higher heritability of lifetime MDD in
women, than in men (Kendler, Gardner, Neale, & Prescott,
2001; Kendler, Gatz, Gardner, & Pedersen, 2006). However,
there is no evidence for qualitative sex differences in the genetic
architecture of depression with the empirical data indicating
that the same genes are expressed in men and women (Eaves
et al., 1997; Middeldorp, Wray, Andrews, Martin, & Boomsma,
2006; Vink et al., 2012).
International molecular genetic studies started to identify gen-
etic variants associated with MDD risk after obtaining large sam-
ple sizes of hundreds of thousands individuals (Howard et al.,
2018; Wray et al., 2018) with broad depression phenotype defini-
tions. Single nucleotide polymorphisms (SNPs) summarized in
Polygenic Risk Score (PRS) explain 1.9% of liability to MDD
(Maier, Visscher, Robinson, & Wray, 2018; Wray et al., 2018).
However, to obtain adequate power in these types of studies,
large samples are needed. The power to detect associations
could be reached with a smaller sample size when there is more
homogeneity both in terms of population and definition of the
depression phenotype (Cai et al., 2015; Mbarek et al., 2017).
Such a large sample size and homogeneity are challenging to
obtain, and usually Genome-Wide Association Studies (GWAS)
meta-analyses of MDD show substantial heterogeneity in depres-
sion assessment between studies and the GWAS methods. One
strategy that could yield homogeneous depression phenotypes
while enabling large sample sizes is online phenotyping by a
valid standardized instrument.
The Biobank Netherlands Internet Collaboration (BIONIC) pro-
ject was started within the Biobanking and BioMolecular resources
Research Infrastructure (BBMRI) in which the presence of MDD
was established in large samples of individuals in a relatively homo-
geneous Dutch population with rich biomarker and ‘omics’ data.
For this purpose, the Lifetime Depression Assessment Self-report
(LIDAS) instrument was developed (see online Supplementary
Material for the cohorts description and LIDAS questionnaire).
LIDAS is an instrument for the assessment of MDD through self-
report, which can be administered online or on paper. It follows
the Diagnostic and Statistical Manual of Mental Disorders (DSM)
criteria and is based on the CIDI short-form (Kessler, Andrews,
Mroczek, Ustun, & Wittchen, 1998). The instrument showed mod-
erate to good sensitivity (66–85%) and specificity (80–86%) in the
validation study compared to depressed cases and controls as iden-
tified by the CIDI, and the lifetime MDD prevalence was estimated
in a range from 19.6% to 20.8% depending on scoring algorithm,
which is consistent with previous studies (Bot et al., 2017).
To evaluate whether MDD phenotype collected using a
standardized online assessment tool (LIDAS) could be used in
epidemiological and genetic association studies in this paper, we
(1) characterize a large group of Dutch study participants taking
part in the BIONIC project, in terms of MDD prevalence for a
range of demographic characteristics, (2) report on the genetic
architecture of MDD as assessed by LIDAS in a genetic and
pedigree-based analysis of data from the Netherlands Twin
Register (NTR) (Boomsma et al., 2018; Willemsen et al., 2013),
(3) test to what extent PRS based on the recent Psychiatric
Genomics Consortium (PGC) meta-analysis of genetic associ-
ation studies of MDD predicts MDD risk in NTR (Wray et al.,
2018). We compare the results to those obtained in large inter-
national studies to provide a ground for the future GWAS
meta-analysis of LIDAS cohorts in the Netherlands.
Methods
MDD phenotype
Data were collected as part of a national collaboration to assess
genetic variants of depression in Dutch cohorts. In 12 Dutch
cohorts [the Netherlands Study of Anxiety and Depression
(NESDA) (Penninx et al., 2008) pilot, NTR (Willemsen et al.,
2013), Lifelines (Scholtens et al., 2015; Stolk et al., 2008),
TRacking Adolescents’ Individual Lives Survey (TRAILS)
(Oldehinkel et al., 2015), TRAILS-CC (Clinical Cohort),
Nijmegen Biomedical Study (NBS) (Galesloot et al., 2017),
Nutrition Questionnaires plus (NQ plus)(Brouwer-Brolsma
et al., 2018), Erasmus Rucphen Family (ERF) (Henneman et al.,
2008), The Hoorn Diabetes Care System cohort (van der
Heijden et al., 2017), The Hoorn Study (Rutters et al., 2017),
The New Hoorn Study (Rutters et al., 2017), Doetinchem Study
(Picavet, Blokstra, Spijkerman, & Verschuren, 2017; Verschuren,
Blokstra, Picavet, & Smit, 2008)], the presence of lifetime and cur-
rent (last year) depression was measured with the LIDAS. The
LIDAS is a questionnaire, which includes the MDD screening
questions according to DSM criteria. If a person did not respond
positive to at least one of the two screening questions about the
two core DSM MDD symptoms of depressed mood and loss of
interest, then the section detailing other symptoms of MDD
was not asked, in line with the DSM MDD criteria. This allows
unaffected controls to fill out the questionnaire faster. The instru-
ment further contained questions on diagnosis or treatment for
depression or other mental disorders, sex, age, level of education,
smoking, physical activity, weight, and height, to be completed by
all participants. The instrument contains 41 questions in total (see
online Supplementary Material).
Current (last year) and lifetime MDD phenotypes were scored
according to DSM MDD criteria. MDD cases were defined as
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those fulfilling at least five of the nine DSM criteria, including one
of the two core symptoms (depressed mood and/or loss of interest)
and the rest out of seven symptoms (loss of energy, sleep problems,
guilt/worthlessness, concentration problems/indecisiveness, psy-
chomotor changes, weight or appetite change, suicidal ideation/
thoughts of death), and replying positively to the question about
serious interference with one’s ability to do one’s job, take care
of household or family, or take care of oneself. Controls were
defined as those who did not have any of the MDD core symptoms
or less than five of the nine DSM MDD criteria or who answered
negatively to the question about serious interference with one’s
ability to do one’s job, take care of household or family, or take
care of oneself. The instrument was validated against an interview
(CIDI) in a subsample of individuals from NESDA (54% recruited
via primary care) and NTR cohorts (Bot et al., 2017).
Prevalence and demographic characteristics of participants
Eight population-based cohorts from the Netherlands were
included in this study. Two cohorts (NESDA pilot and
TRAILS-CC), in which the number of MDD cases was overrepre-
sented due to study design, were excluded. The Hoorn Diabetes
Care System cohort, The Hoorn Study, and The New Hoorn
Study, in which persons with diabetes or pre-diabetes were over-
sampled, were combined into one Hoorn studies cohort. If infor-
mation about family relatedness was available for cohorts (NTR),
one person per family was randomly sampled.
We described the demographic characteristics such as sex, age,
education, smoking status, physical activity, and body mass index
(BMI) in each cohort and in the total sample. We categorized
education into three levels (low, medium, and high) irrespective
of whether diploma or certificate was received, with the exception
of the high education group. If no diploma or certificate was
received in that group, a participant would be included in the
medium education group. For the Lifelines cohort, the question
about education was slightly different and already assumed dip-
loma or certificate being received and data were categorized taking
it into account (online Supplementary Material). Age was classi-
fied into 18–39, 40–59, 60+ years. We inspected visually the dis-
tribution of age, height, weight, and BMI and excluded possible
typos/outliers in age (120 years old, N = 1), height (<150 and
>220 cm, N = 47), weight (<45 and >200 kg, N = 22), and BMI
(<15 and >50, N = 25 after height and weight exclusion).
Smoking status was represented by three groups, who answered
to the question ‘Do you smoke?’ as (1) no, I never smoked; (2)
I do not smoke at the moment, but I smoked in the past; and
(3) yes. Physical activity was represented by three groups, namely
by those who answered to the question ‘Do you at least once per
week engage in physical activities in your leisure time that cause
sweating?’ as (1) no; (2) 1x/2x per week; (3) 3x/4x per week or
more. We categorized BMI (kg/m2) into four groups: underweight
(<18.5); normal weight (18.5–24.9); overweight (25.0–29.9); obes-
ity (⩾30.0). For some studies, the categorization resulted in small
sample size per subgroup and such specific subgroups were
excluded from analyses. For example, age group of 18–39 years
was not represented in the Doetinchem and Hoorn Studies
(N = 1) and groups of 40–59 and 60+ years were not represented
in TRAILS (N = 0). The underweight subgroup was excluded from
meta-analysis due to lack of observations in the majority of
cohorts.
We first calculated the prevalence of MDD in each cohort. We
assumed that true underlying effect (estimated proportion) is not
the same across studies, because BIONIC cohorts differ between
each other for a range of demographic characteristics.
Therefore, we meta-analyzed results in a random-effects model
in R package ‘meta’ using the inverse variance method
(Schwarzer, 2007). Random-effects model means that estimated
effect could differ due to unknown reasons (Serghiou &
Goodman, 2019). We estimated the proportion of heterogeneity
as quantified by I2 statistic, which ranges from 0% to 100%
(Higgins & Thompson, 2002). We then performed the same ana-
lysis in subgroups according to the six demographic characteris-
tics listed above (sex, age, education, smoking status, physical
activity, and BMI). We tested whether differences between preva-
lence in each subgroup (e.g. low, medium, and high education)
were statistically significant. We corrected for multiple testing
using Bonferroni correction 0.05/12 = 4 × 10−3 taking into
account two phenotypes (current and lifetime MDD) × 6 tests.
We used meta-regression (Schwarzer, 2007) using subgroup strata
(e.g. low, medium, and high education) as study-level covariates to
explore the effect of the covariate on the amount of heterogeneity
(I2) between cohorts. We tested the statistical significance of mod-
erators using the omnibus test and QM test statistic as defined in
R metafor package (Viechtbauer, 2010). Finally, we performed
sensitivity analysis using a leave-one-out approach to identify
influential cohorts.
To test whether BIONIC participants differ from the general
population in terms of the prevalence of MDD and depression-
related traits, we compared NTR participants that did participate
in BIONIC and other NTR non-BIONIC participants in terms of
depression-related traits such as (1) neuroticism, assessed by NEO
Five-Factor Inventory (NEO-FFI) (Costa Jr & McCrae, 1989;
McCrae & Costa Jr, 2007); (2) anxiety, assessed through the
Anxious-Depressed scale of Adult Self Report (ASR) question-
naire (Achenbach & Rescorla, 2003); (3) depression, assessed
through Hospital Anxiety and Depression Scale (HADS)
(Zigmond & Snaith, 1983); and (4) answer to the question ‘Ever
been in contact with counselling professionals for problems unre-
lated to physical health?’, which were available in NTR (online
Supplementary Material).
Heritability of LIDAS instrument in NTR
Within NTR, extended family data were collected allowing for
genetically informed analysis to estimate narrow-sense heritability
(h2, further in this paper, we will refer to it simply as heritability),
that is the amount of phenotypic variation in case–control status
that is accounted for by additive genetic factors (Boomsma et al.,
2018; Willemsen et al., 2013). For these analyses, a strict defin-
ition of controls was applied by excluding individuals with self-
reported diagnosis/treatment of any other psychiatric disorder.
We estimated heritability of current and lifetime MDD. To
benchmark the analyses, we estimated the heritability of height
and weight. Extended twin-family data were available for 18 838
individuals with age ⩾18 years. There were 13 868 (1390 cases
and 12 478 controls) and 16 142 (3664 cases and 12 478 controls)
individuals in whom the presence of current and lifetime MDD,
respectively, could be ascertained. Data on self-reported height
and weight were available for 18 113 and 18 102 individuals,
respectively. Of these, individuals, who reported different sex
(transgender, N = 4), whose sex or age was missing (N = 39), or
who could not be linked to a pedigree because of ambiguous
information on biological relatedness (N = 1) were excluded
from all analyses.
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For individuals with genotype data available, their ancestry was
checked and non-Dutch participants were excluded (N = 351, see
online Supplementary Material) (Abdellaoui et al., 2013). In
total, 13 571 participants [1358 cases and 12 213 controls; 8399
pedigrees; 2345 monozygotic (MZ) and 2882 dizygotic (DZ) twin
pairs] were included in the analysis of current MDD.
Accordingly, 15 796 individuals (3583 cases and 12 213 controls;
9307 pedigrees; 2596 MZ and 3236 DZ twin pairs) were included
in the estimation of lifetime MDD heritability. For height and
weight, we additionally excluded possible typos/outliers outside of
5 standard deviations (S.D.) from the mean (N = 8 for height and
N = 16 for weight). In total, 17 711 individuals (9954 pedigrees;
2805 MZ and 3518 DZ twin pairs) with data on height and 17
693 individuals (9941 pedigrees; 2803 MZ and 3514 DZ twin
pairs) with data on weight ended up in these heritability analyses.
We estimated additive genetic (A), shared (C), and unique
environmental (E) variance components in the Mendel software
in a linear regression framework (Boomsma et al., 2018; Lange
et al., 2013). Age and sex were added as fixed covariates. The addi-
tive genetic (A) variance relative to the total variance (the sum of
A, C, and E) represents the heritability (h2). Note that in our data,
C component was represented by environment shared by twins
(both MZ and DZ) up till late adolescence (age 18) when they
typically leave the parental household.
MDD prediction based on PRS
With the increasing samples sizes in GWAS meta-analyses of
MDD, more genetic makers, i.e. SNPs, have been identified as
associated with MDD. When such marker effects are summarized
in one score (Polygenic Risk Score, PRS profile) at an individual
level, calculated as a sum of SNP risk alleles weighted by each
risk allele effect identified in large MDD GWAS meta-analysis,
it can be used to predict MDD in other datasets to assess its pre-
dictive power (Wray et al., 2014).
Within NTR, there were 4782 individuals (1078 cases and 3704
controls) with SNP and lifetime MDD data (see online
Supplementary Material for the description of genotyping, imput-
ation, and PRS calculation). For each individual, a PRS profile was
computed based on summary statistics from the latest PGC GWAS
meta-analysis of MDD in the individuals of European ancestry to
date (Wray et al., 2018). The target dataset, the one on which the
MDD phenotype will be predicted, was excluded from the discov-
ery of GWAS meta-analysis, which was based on all other PGC
cohorts. We computed PRS using LDpred software (Vilhjálmsson
et al., 2015) assuming causal fraction of SNPs of 0.3 (see online
Supplementary Material for details). To explore how well the
PRS based on the broad definition of depression predicts LIDAS
lifetime MDD, we (1) plotted the proportion of LIDAS MDD
cases for each decile of PRS distribution; and (2) predicted
LIDAS MDD case–control status of the participants in NTR
from their corresponding PRS profiles. For the latter, we used gen-
eralized estimating equations with exchangeable correlation struc-
ture to account for relatedness within the dataset (Minică, Dolan,
Kampert, Boomsma, & Vink, 2015). Age, sex, 10 principal compo-
nents, and six genotyping chips were included as fixed covariates.
Finally, we estimated a genetic correlation between MDD as
assessed by LIDAS and clinical MDD as assessed by CIDI, as esti-
mated in the Mendel software package for pedigree analyses
(Lange et al., 2013). Data on both these measurements were avail-
able in NTR and NESDA studies (see online Supplementary
Material for details).
Results
Demographic and lifestyle characteristics
The total number of participants reached 22 623 and 22 624 indi-
viduals for the current and lifetime MDD as defined by LIDAS.
The total sample size per cohort slightly varies between current
and lifetime MDD depending on whether last year episode item
was filled in by a participant (Fig. 1). Cohort-specific number
of participants and proportions of males/females, low/medium/
high education, smoking status, physical activity, and mean
(S.D.) of age and BMI are presented in Table 1. Proportion of
males was smaller than the proportion of females in the majority
of the cohorts and in the total sample, ranging from 33% in NTR
to 49% in NBS, except for NQplus (56%) and The Hoorn Studies
(60%). TRAILS was the youngest cohort with mean age 25.1
(S.D. = 0.6), whereas other cohorts mean age estimates ranged
from 42.3 (S.D. = 16.3) in NTR to 68.1 (S.D. = 8.3) in The Hoorn
Studies. Cohorts varied in the proportion of education level
with the majority of participants falling into medium or high edu-
cation groups. Most participants were either non-smoking or
smoking in the past across cohorts, except in TRAILS, where
the proportion of smokers was larger than that of non-smokers.
Physical activity was distributed similarly across cohorts with
most participants exercising 1–2 times per week (Table 1). The
younger TRAILS cohort followed a different trend, where the pro-
portion of those who exercise 3–4 times per week or more was
similar to those who exercise 1–2 times per week (Table 1).
BMI was similar across all cohorts (M total = 25.3, S.D. total =
1.0) with a somewhat increased mean estimate in The Hoorn
Studies. Comparison of BIONIC respondents v. other participants
in NTR showed that depression-related traits were similar in
BIONIC NTR respondents and other NTR respondents (online
Supplementary Material). Levels of anxiety, depression, neuroti-
cism, and ‘contact with counselling professionals for problems
unrelated to physical health’ were very similar across both groups
(online Supplementary Material), indicating that participants in
the BIONIC sample were not very different from other NTR par-
ticipants, and thus may represent the general population.
Prevalence
The pooled prevalence estimates of current and lifetime MDD in
the total sample were 6.7% (95% CI 5.3–8.4%) and 18.1% (95% CI
16.1–20.3%), respectively (Fig. 1).
Prevalence estimates per strata are depicted in Fig. 2 and forest
plots from the subgroup analyses are shown in online
Supplementary Figs S2 and S3 for current and lifetime MDD,
respectively. As expected, the prevalence of lifetime MDD was sig-
nificantly lower in males (14.5%) than in females (21.0%).
Prevalence of current MDD was following the same trend but
this difference was not significant after correction for multiple
testing (5.2% in males, 7.9% in females). Prevalence of both cur-
rent and lifetime MDD was significantly lower in the age sub-
group of 60 years and older (Fig. 2). We did not observe a
significant difference in prevalence estimates in education level
and physical activity strata for both current and lifetime MDD
(Fig. 2). Estimates of prevalence were larger in smokers than in
non-smokers with a significant difference between groups for
both current and lifetime MDD. We observed a trend toward lar-
ger prevalence in the participants with obesity compared to par-
ticipants with normal weight and overweight; however, it was not
statistically significant for both current and lifetime MDD (Fig. 2).
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The heterogeneity between studies was substantial for both
current MDD [I2 = 94% (95% CI 91–96%)] as well as for lifetime
MDD [I2 = 92% (95% CI 87–95%)]. We observed a reduced
amount of heterogeneity between studies when data were strati-
fied by sex and age groups (online Supplementary Figs S2 and
S3), suggesting that part of the study heterogeneity for current
and lifetime MDD depended on differences in samples in age
and sex as suggested also by results of meta-regression.
Results of meta-regression showed that sex- and age-level cov-
ariates as defined by subgroups were significant contributors to
heterogeneity between studies. Sex accounted for 24% [QM
(df = 1) = 5.5, p = 0.02] and 72% [QM (df = 1) = 21.8, p < 0.0001]
of heterogeneity for current and lifetime MDD. Age accounted
for 80% [QM (df = 2) = 51.5, p⩽0.0001] and 75% [QM (df = 2)
= 44.7, p < 0.0001] of variability between studies.
We performed a sensitivity analysis using leave-out one study
at a time approach, which showed that no single study had a
substantial influence on the meta-analysis results for current
and lifetime MDD prevalence (online Supplementary Fig. S4).
Heritability and PRS analyses
The estimated heritability of current and lifetime MDD were
comparable and comprised 0.34 (S.E. = 0.02) and 0.30 (S.E. =
0.02), respectively. To benchmark the analysis, we report
heritability estimates of height and weight, which were 0.81 (S.E.
= 0.009) and 0.55 (S.E. = 0.01). Estimates of A, C (shared environ-
ment for twins), and E variance components with their standard
errors (S.E.) are reported for each phenotype in online
Supplementary Table S1. All variance components were signifi-
cantly different from zero for all traits, except the C component
for current and lifetime MDD, suggesting that twins shared envir-
onment does not contribute to the variation in MDD status. The
direction of sex effect was negative for males (−0.05 for lifetime
and −0.02 for current MDD) and positive for females (0.05 for
lifetime and 0.02 for current MDD), indicating a higher MDD
risk for females.
We observed a positive linear relationship between deciles
based on the PRS distribution and the proportion of lifetime
MDD cases (Fig. 3). The proportion of cases increases linearly
with an increase of PRS, indicating that the group of people
with higher PRS have a larger proportion of MDD cases as
defined with the LIDAS (Fig. 3). The PRS significantly predicted
lifetime MDD case/control status (OR 1.23, 95% CI 1.15–1.32).
Pseudo-R2 indicating the proportion of variance explained in
the phenotype by the PRS was 1.20%, and 1.47% on liability
scale (Lee, Goddard, Wray, & Visscher, 2012).
The number of participants with both LIDAS and CIDI data
was 1682 individuals (186 cases and 1496 controls for LIDAS
and 68 cases and 1614 controls for CIDI MDD, see online
Fig. 1. Pooled estimates of (a) current MDD and (b) lifetime MDD prevalence as measured with LIDAS.
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Table 1. Demographic characteristics of BIONIC participants in whom lifetime MDD status could be determineda
Doetinchem ERF NBS NQplus TRAILS Hoorn Studies NTRb Lifelinesc Total
N 2663 220 1520 924 977 901 9895 5524 22 624
Sex, N (%)
Males 1276 (48.2%) 106 (48.2%) 743 (49.0%) 515 (55.7%) 403 (41.2%) 538 (59.7%) 3307 (33.4%) 2275 (41.1%) 9163 (40.5%)
Females 1374 (51.8%) 114 (51.8%) 774 (51.0%) 409 (44.3%) 574 (58.8%) 363 (40.3%) 6588 (66.6%) 3258 (58.9%) 13 454 (59.5%)
Age, years
Mean (S.D.) 65.6 (9.0) 55.6 (12.5) 63.2 (13.4) 58.7 (11.0) 25.1 (0.6) 68.1 (8.3) 42.3 (16.3) 55.4 (9.8) 50.7 (10.8)
N 2623 220 1517 924 977 899 9874 5533 22 567
Education, N (%)
Low 600 (23.5%) 83 (38.1%) 198 (13.7%) 50 (5.5%) 13 (1.3%) 232 (27.5%) 588 (6.0%) 85 (1.6%) 1849 (8.4%)
Medium 1172 (45.8%) 88 (40.4%) 478 (33.1%) 316 (34.6%) 511 (52.3%) 399 (47.3%) 4817 (49.5%) 3133 (57.6%) 10 914 (49.3%)
High 785 (30.7%) 47 (21.6%) 768 (53.2%) 547 (59.9%) 453 (46.4%) 213 (25.2%) 4336 (44.5%) 2219 (40.8%) 9368 (42.3%)
Smoking, N (%)
Never 1104 (41.7%) 91 (41.4%) 585 (38.5%) 458 (49.6%) 268 (27.7%) 292 (32.6%) 5602 (56.6%) 2501 (45.2%) 10 901 (48.2%)
Past smoker 1215 (45.9%) 105 (47.7%) 789 (51.9%) 418 (45.2%) 350 (36.2%) 530 (59.2%) 3162 (32.0%) 2296 (41.5%) 8865 (39.2%)
Current smoker 328 (12.4%) 24 (10.9%) 146 (9.6%) 48 (5.2%) 350 (36.2%) 74 (8.3%) 1127 (11.4%) 734 (13.3%) 2831 (12.5%)
Physical activity N (%)
No 562 (21.4%) 67 (30.6%) 455 (30.0%) 162 (17.5%) 237 (24.8%) 325 (36.3%) 2150 (21.7%) 1155 (20.9%) 5113 (22.7%)
1/2 t.p.w. 1437 (54.7%) 114 (52.1%) 770 (50.7%) 528 (57.1%) 393 (41.2%) 397 (44.3%) 5254 (53.1%) 3001 (54.2%) 11 894 (52.7%)
3/4 or more t.p.w. 626 (23.8%) 38 (17.4%) 293 (19.3%) 234 (25.3%) 325 (34.0%) 174 (19.4%) 2488 (25.2%) 1377 (24.9%) 5555 (24.6%)
BMI
Mean (S.D.) 26.1 (3.8) 26.7 (4.2) 25.3 (3.8) 25.0 (3.7) 24.0 (4.2) 28.6 (4.6) 24.6 (4.2) 26.0 (4.2) 25.3 (1.0)
N 2623 213 1488 909 954 884 9709 5516 22 296
t.p.w., times per week.
aFor some individuals, sex, age, education, smoking, physical activity, or BMI were missing; however, they are still included in total prevalence calculation.
bOnly unrelated individuals. The total sample size of NTR data with LIDAS assessment is 18 838.
cFor Lifelines, demographic characteristics were calculated on the full data, including those for whom lifetime MDD status could not be determined.
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Supplementary Table S2). The time interval between assessment by
CIDI and by LIDAS was substantial. Cases in NTR and NESDA
were assessed about 9 years before LIDAS (Middeldorp et al.,
2006; Sullivan et al., 2009), thus recall bias may explain a change
in status. Controls in NESDA were identified as scoring with no
depression on all CIDI assessments, including the most recent
one a few months before completing LIDAS. The genetic correl-
ation between MDD assessed by LIDAS and by CIDI was 0.70.
Fig. 2. Pooled estimates of current (a) and (b) lifetime MDD prevalence as measured with LIDAS per subgroup (sex, age, education, smoking, physical activity, and
obesity). Q, Cochran’s Q; df, degrees of freedom; p, p value from the subgroup analysis of (a) current and (b) lifetime MDD; y.o., years old; t.p.w., times per week.
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Discussion
In the current study, we addressed a question of whether MDD
phenotype collected using a standardized online assessment tool
(LIDAS) could be used in epidemiological and genetic association
studies. The instrument was validated against a diagnostic inter-
view in a previous study (Bot et al., 2017). Here we reported
the prevalence of current and lifetime MDD in eight Dutch
cohorts involving 22 623 participants, and explored the genetic
architecture of MDD as established by the LIDAS. We investi-
gated whether the prevalence of current and lifetime MDD dif-
fered according to sex, age, education, smoking status, physical
activity, and BMI.
Prevalence of current MDD in BIONIC was estimated as 6.7%
(95% CI 5.3–8.4%) for the total sample and as 5.2% (95% CI 3.9–
6.9%) for males and 7.9% (95% CI 6.4–9.7%) for females. This is
in line with previous studies conducted in the Netherlands, where
12-month MDD prevalence was 5.8% with estimates for males as
4.1% and for females as 7.5% (Bijl et al., 1998). A study published
about 14 years later showed similar estimates for the total sample
(5.2%), as well as for males (4.1%) and females (6.3%) (de Graaf
et al., 2012). Lifetime MDD prevalence in our data was estimated
as 18.1% (95% CI 16.1–20.3%) with significantly different esti-
mates for males (14.5%, 95% CI 12.9–16.3%) and females
(21.0%, 95% CI 19.0–23.3%). Lifetime MDD prevalence estimates
were in line with the estimate found in the two previous studies in
the Netherlands (overall prevalence 15.4/18.7%, prevalence in
males 10.9/13.1%, and prevalence in females 20.1/24.4%) (Bijl
et al., 1998; de Graaf et al., 2012). With our data, we largely con-
firmed previously reported socio-demographic and lifestyle corre-
lates of MDD. Previous studies indicated that the current MDD
prevalence decreases with age (Bijl et al., 1998; de Graaf et al.,
2012; Ohayon, 2007), which we confirmed in our study. For life-
time MDD, we observed that the prevalence is similar in
middle-aged and younger adults, but is much lower in the age
subgroup of 60+. This has been reported before, but is counter
intuitive as depressive episodes are likely to accumulate in life,
and could indicate recall bias, selective survival, or a cohort effect
(Andrade et al., 2000; Kessler et al., 2007, 2010). Significant differ-
ence in prevalence between males and females, different age
groups, and effect of these variables on heterogeneity between
studies warrants further sex- and age-specific research as different
etiological factors could be involved in liability to MDD in these
subgroups. We observed a trend of increased prevalence of both
current and lifetime MDD in relation to smoking and higher
BMI, which is in line with previous research (Fergusson,
Goodwin, & Horwood, 2003; Glassman et al., 1990; Ohayon,
2007; Weinberger et al., 2017). Note that the association between
increased MDD prevalence and higher BMI could be driven by
The Hoorn Studies, which are represented by older participants
and include type 2 diabetes patients. We found similar current
and lifetime MDD prevalence in education and physical activity
strata, although there is a trend to a lower MDD prevalence in
higher education group, which has been shown in previous
research (Andrade et al., 2000; Ohayon, 2007).
MDD is a common and multifactorial disorder with many
genetic and environmental factors contributing to the risk. The
amount of additive genetic variation that contributes to the vari-
ation in liability to MDD (heritability, h2) is an important popu-
lation characteristic of the phenotype. Heritability of current and
lifetime MDD in our data were 0.34 (S.E. = 0.02) and 0.30 (S.E. =
0.02), respectively. This is in line with the meta-analytic estimate
based on previous studies of twin data (h2 = 34%) (Polderman
et al., 2015). To benchmark the analysis, we estimated heritability
for height and weight, which were highly consistent with previous
research (Dubois et al., 2012; Elks et al., 2012; Silventoinen et al.,
2003). PRS profiles of NTR individuals computed based on the
results of an international GWAS meta-analysis using a rather
broad definition of MDD were significantly associated with the
risk of lifetime MDD as assessed by LIDAS, although the amount
of variation explained by PRS profile on liability scale was some-
what lower in LIDAS (R2 = 1.47%) than in the GWAS
meta-analysis (R2 = 1.9%) (Wray et al., 2018). In addition, the
results of the genetic correlation analysis suggested that similar
genetic factors are involved to a large extent (rg = 0.70) between
MDD assessed by LIDAS and CIDI. Note, however, that the sam-
ple size was not large (N total = 1682 persons) and that there was
a 9-year interval between the two assessments.
In conclusion, the similarity of MDD prevalence and genetic
architecture in BIONIC as compared to other Dutch general
population studies of MDD suggests that the BIONIC data
assessed with LIDAS are suitable to use in future epidemiological
and genetic studies of MDD. Studying etiological factors of MDD
is often difficult and costly. With the introduction of the LIDAS,
more opportunities for the assessment of MDD in the context of
other health-related or demographic studies become available and
this project contributes to the opportunities to collect and need of
increased sample size that is needed for a better understanding of
the biological and genetic aspects of MDD.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291720000100
Acknowledgements. BBMRI-NL Rainbow project Phenomics 2.0 – proof of
principle for major depressive disorder (RP-12). Acknowledgements and
financial support per each cohort can be found in online Supplementary
Material.
Fig. 3. Proportion of lifetime MDD cases in NTR plotted against deciles of PRS profiles
distribution. For each group of individuals falling into ith decile of PRS distribution,
the proportion of cases was calculated. This plot shows the relationship between
the increasing value of PRS profile and the increased number of MDD cases. The
line plotted through the points is a linear regression line with shaded area around
it depicting the 95% confidence interval.
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